Familial ALS accounts for 8% of all cases, analysis suggests
The proportion of people diagnosed with familial amyotrophic lateral sclerosis (ALS) among all cases is 8%, according to a…
Articles by Steve Bryson, PhD
Juvenile-onset ALS linked to new SPTLC2 mutation: Study
A previously unknown mutation in the SPTLC2 gene was identified in two patients who developed juvenile-onset amyotrophic lateral sclerosis…
Top 10 ALS stories of 2023
Throughout 2023, ALS News Today brought you daily coverage of the latest clinical research and scientific breakthroughs related to…
Biomarker data insufficient to support CNM-Au8’s approval: FDA
Early data from Phase 2 programs showing that CNM-Au8, an oral therapy candidate for amyotrophic lateral sclerosis (ALS),…
Relyvrio reduces inflammatory biomarkers in ALS: CENTAUR data
Treatment with Relyvrio (sodium phenylbutyrate and taurursodiol) significantly reduced blood levels of neuroinflammatory biomarkers in people with amyotrophic…
Neurotoxins from bacteria found in dust around Great Salt Lake
Toxic compounds produced by cyanobacteria, which have been identified as risk factors for developing amyotrophic lateral sclerosis (ALS), were…
SOL-257 gene therapy improves outcomes in 2 ALS mouse models
SOL-257, an experimental one-time gene therapy, was well tolerated and significantly improved disease outcomes in two distinct mouse models of…
Pregnancy can speed ALS severity and progression, review study finds
Pregnancy can worsen the progression of amyotrophic lateral sclerosis (ALS), regardless of whether symptom onset occurs before or during…
Interferon-gamma therapy may help delay familial ALS: Cell study
People with amyotrophic lateral sclerosis (ALS) due to mutations in the FUS gene may benefit from interferon-gamma treatment to…
New cell-based system may help speed treatment discovery
A newly developed cell-based system, made of nerve cells connected to muscle fibers, may allow the rapid, large-scale screening of…